Betram Pitt

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis
    Pascal Meier
    The Heart Hospital London, University College London Hospital Trust, London, UK
    BMC Med 10:62. 2012
  2. ncbi The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure
    Bertram Pitt
    School of Medicine, University of Michigan, Ann Arbor, MI, USA
    Heart Fail Rev 17:573-9. 2012
  3. ncbi Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease
    Bertram Pitt
    Division of Cardiology, University of Michigan, USA
    J Renin Angiotensin Aldosterone Syst 4:164-8. 2003
  4. ncbi Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI, USA
    Mol Cell Endocrinol 217:53-8. 2004
  5. ncbi Generic drugs in cardiology: will they reduce health care costs?
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    J Am Coll Cardiol 44:10-3. 2004
  6. ncbi Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
    Nat Clin Pract Cardiovasc Med 2:70-1. 2005
  7. ncbi Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Bertram Pitt
    University of Michigan School of Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48104, USA
    Curr Heart Fail Rep 6:112-6. 2009
  8. ncbi A primer on aldosterone for gynecologists/obstetricians
    Bertram Pitt
    Department of Internal Medicine, University of Michigan, Ann Arbor, USA
    J Reprod Med 52:153-8. 2007
  9. ncbi Prehypertension. To treat, or not to treat: that is the question
    Betram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Am J Hypertens 20:492. 2007
  10. ncbi Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death
    Bertram Pitt
    University of Michigan School of Medicine, Division of Cardiology, University Hospital, 1500 East Medical Center Dr, Ann Arbor, MI 48109-0366, USA
    Circulation 115:2976-82; discussion 2982. 2007

Collaborators

Detail Information

Publications83

  1. ncbi Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis
    Pascal Meier
    The Heart Hospital London, University College London Hospital Trust, London, UK
    BMC Med 10:62. 2012
    ..The purpose of this systematic review and meta-analysis of observational studies was to explore the impact of the collateral circulation on the risk for restenosis...
  2. ncbi The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure
    Bertram Pitt
    School of Medicine, University of Michigan, Ann Arbor, MI, USA
    Heart Fail Rev 17:573-9. 2012
    ..The safety and efficacy of this hypothesis is currently under investigation in the NHLBI sponsored TOPCAT trial...
  3. ncbi Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease
    Bertram Pitt
    Division of Cardiology, University of Michigan, USA
    J Renin Angiotensin Aldosterone Syst 4:164-8. 2003
    ..This hypothesis will, however, require further prospective evaluation...
  4. ncbi Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI, USA
    Mol Cell Endocrinol 217:53-8. 2004
    ....
  5. ncbi Generic drugs in cardiology: will they reduce health care costs?
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    J Am Coll Cardiol 44:10-3. 2004
    ..Thus, the apparent savings resulting from the introduction of generic drugs may not be fully realized unless the government and other third-party payers take a more active role in postgraduate drug education and investigation...
  6. ncbi Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
    Nat Clin Pract Cardiovasc Med 2:70-1. 2005
  7. ncbi Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Bertram Pitt
    University of Michigan School of Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48104, USA
    Curr Heart Fail Rep 6:112-6. 2009
    ..This article reviews the efficacy and safety of adding another renin-angiotensin-aldosterone system inhibitor or blocker to an ACE-I or an angiotensin receptor blocker plus a BB in patients with HF-LVSD...
  8. ncbi A primer on aldosterone for gynecologists/obstetricians
    Bertram Pitt
    Department of Internal Medicine, University of Michigan, Ann Arbor, USA
    J Reprod Med 52:153-8. 2007
    ..An historical perspective on the role of aldosterone in the pathophysiology of hypertension and heart disease, and data supporting the advantages of blocking the mineralocorticoid receptor with anti-aldosterone agents...
  9. ncbi Prehypertension. To treat, or not to treat: that is the question
    Betram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Am J Hypertens 20:492. 2007
  10. ncbi Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death
    Bertram Pitt
    University of Michigan School of Medicine, Division of Cardiology, University Hospital, 1500 East Medical Center Dr, Ann Arbor, MI 48109-0366, USA
    Circulation 115:2976-82; discussion 2982. 2007
  11. ncbi Aldosterone blockade in patients with chronic heart failure
    Bertram Pitt
    University of Michigan School of Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cardiol Clin 26:15-21, v. 2008
    ..However, these hypotheses must be confirmed in well-designed, large-scale, prospectively randomized studies...
  12. ncbi Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI, USA
    Curr Atheroscler Rep 10:288-94. 2008
    ..The decision in regard to the timing and role of revascularization in patients with unstable CAD, although still evolving, is somewhat less controversial. The major focus of this discussion is, therefore, on the patient with stable CAD...
  13. ncbi Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study
    Bertram Pitt
    University of Michigan Health System, Ann Arbor, Mich, USA
    Circulation 108:1831-8. 2003
    ..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
  14. ncbi New insights into the role of aldosterone in cardiorenal disease and the clinical implications. Introduction
    Bertram Pitt
    University of Michigan, Ann Arbor 48109-0366, USA
    Am Heart J 144:S1. 2002
  15. ncbi Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?
    Bertram Pitt
    Division of Cardiology, University of Michigan Medical School, Ann Arbor 48109 0366, USA
    Am J Hypertens 15:22S-27S. 2002
    ..The ACE inhibitors remain the current therapy of choice in treating heart failure until further outcomes trial data become available; however, ARB are a reasonable alternative in patients intolerant of ACE inhibitors...
  16. ncbi Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Bertram Pitt
    University of Michigan, Ann Arbor, USA
    N Engl J Med 348:1309-21. 2003
    ....
  17. ncbi Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
    B Pitt
    Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    N Engl J Med 341:70-6. 1999
    ..In this study, we compared percutaneous coronary revascularization with lipid-lowering treatment for reducing the incidence of ischemic events...
  18. ncbi Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  19. ncbi Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
    Sverre E Kjeldsen
    University of Michigan Health System, Ann Arbor, Michigan, USA
    Blood Press 17:7-17. 2008
    ..3%) and diabetic patients <130/80 mmHg (43.3%) at 12 months of follow-up than any other large outcomes trial. We have analyzed baseline predictors of BPs and BP control at 12 months...
  20. ncbi Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis
    Ragavendra R Baliga
    Department of Internal Medicine, Division of Cardiovascular Medicine at the University of Michigan, Ann Arbor, Michigan, USA
    J Card Fail 12:250-6. 2006
    ..A randomized controlled trial is necessary to accurately define the clinical effects of spironolactone in patients with mild heart failure...
  21. ncbi Aldosterone blockade in patients with systolic left ventricular dysfunction
    Bertram Pitt
    University of Michigan School of Medicine, 3901 Taubman Center, Ann Arbor, Mich 48109-0366, USA
    Circulation 108:1790-4. 2003
  22. ncbi Aldosterone receptor antagonists for heart failure: current status, future indications
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI, USA
    Cleve Clin J Med 73:257-60, 264-8. 2006
    ..We review the evidence and indications...
  23. ncbi Cardiovascular events during differing hypertension therapies in patients with diabetes
    Michael A Weber
    Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York 11203, USA
    J Am Coll Cardiol 56:77-85. 2010
    ..The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases cardiovascular events...
  24. ncbi Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    J Card Fail 8:S491-3. 2002
    ....
  25. ncbi The role of aldosterone blockade in patients with heart failure
    Bertram Pitt
    The University of Michigan School of Medicine, Ann Arbor, MI 48170, USA
    Heart Fail Rev 10:79-83. 2005
    ..This article will review the clinical evidence supporting the use of aldosterone blocking agents (AB)in patients with HF and speculate on some potential future uses...
  26. ncbi The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction
    Mihai Gheorghiade
    Department of Medicine, Center for Cardiovascular Quality and Outcomes, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Am Heart J 158:437-43. 2009
    ....
  27. ncbi Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study
    Sonal Korgaonkar
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48103, USA
    Clin J Am Soc Nephrol 5:762-9. 2010
    ..The relationship between serum potassium (S(K)) and mortality in chronic kidney disease (CKD) has not been systematically investigated...
  28. ncbi Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade
    Bertram Pitt
    University of Michigan Medical Center, William Beaumont Hospital, Ann Arbor, Michigan 48109, USA
    Am J Cardiol 97:26F-33F. 2006
    ..To achieve needed improvements in outcomes in this population, early and consistent initiation of these evidence-based, guideline-recommended therapies in all eligible patients is crucial...
  29. ncbi Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level
    Barry E Bleske
    University of Michigan, College of Pharmacy, Ann Arbor, Michigan 48109 1065, USA
    J Am Coll Cardiol 47:338-41. 2006
    ....
  30. ncbi Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%
    Bertram Pitt
    University of Michigan Medical Center, Alfred Taubman Health Care Center, 1500 East Medical Center Drive, Ann Arbor, 48109, USA
    Eur J Heart Fail 8:295-301. 2006
    ....
  31. ncbi Aldosterone blockade in post-acute myocardial infarction heart failure
    Bertram Pitt
    University of Michigan Medical Center, William Beaumont Hospital, Cardiovascular Department, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Clin Cardiol 29:434-8. 2006
    ..Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented...
  32. ncbi Exceptional early blood pressure control rates: the ACCOMPLISH trial
    Kenneth Jamerson
    University of Michigan Health System, Division of Cardiovascular Medicine, Ann Arbor, Michigan 48106 0739, USA
    Blood Press 16:80-6. 2007
    ..At baseline, 97% of subjects were treated with anti-hypertensive medication at entry, but only 37% of participants had blood pressure (BP) control (<140/90 mmHg). Single-tablet combination therapy may improve control rates...
  33. ncbi Effect of losartan in aging-related endothelial impairment
    Sanjay Rajagopalan
    Department of Internal Medicine, Divisions of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109 0273, USA
    Am J Cardiol 89:562-6. 2002
    ..47, p = 0.05). Thus, administration of losartan for a duration of 6 weeks has favorable effects on inflammatory markers in healthy older subjects, but does not alter peripheral conduit endothelial function...
  34. ncbi Lipid levels after acute coronary syndromes
    Bertram Pitt
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    J Am Coll Cardiol 51:1440-5. 2008
    ..This analysis from the LUNAR (Limiting UNdertreatment of lipids in ACS with Rosuvastatin) study assessed lipid changes 1 to 4 days after onset of acute coronary syndromes (ACS), before initiation of study treatment...
  35. ncbi History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure
    Bertram Pitt
    University of Michigan, 1500 E Medical Center Dr, 3910 Taubman Center, Ann Arbor, MI 48109 0366, USA
    Hypertension 52:271-8. 2008
    ..91; 95% CI: 0.76 to 1.10; P=0.331). Eplerenone should, therefore, be prescribed to all of the post-acute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure regardless of Hx-HTN...
  36. ncbi Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women
    Richard A Preston
    Division of Clinical Pharmacology and Pharmacokinetics Clinical Research Center, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    Am J Hypertens 18:797-804. 2005
    ..Because of a significant aldosterone antagonist activity, we studied the effects of DRSP/E2 on serum potassium (K) and blood pressure (BP) in hypertensive postmenopausal women with and without diabetes mellitus...
  37. ncbi Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
    Bertram Pitt
    University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
    Circulation 118:1643-50. 2008
    ..This subanalysis examined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)...
  38. ncbi Aldosterone as a target in congestive heart failure
    Sanjay Rajagopalan
    University of Michigan School of Medicine, Ann Arbor, MI, USA
    Med Clin North Am 87:441-57. 2003
    ..0 mg/dL and serum potassium levels are < 5.0 meq/L at baseline...
  39. ncbi Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control
    Kenneth A Jamerson
    Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    Hypertension 57:174-9. 2011
    ....
  40. ncbi Role of aldosterone blockade in heart failure
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI 48109-0366, USA
    Heart Fail Clin 1:49-56. 2005
  41. ncbi Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    J Am Coll Cardiol 46:425-31. 2005
    ....
  42. ncbi Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    Kenneth Jamerson
    Division of Cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr, Lobby M, Ann Arbor, MI 48106, USA
    N Engl J Med 359:2417-28. 2008
    ....
  43. ncbi New York Heart Association functional class predicts exercise parameters in the current era
    Stuart D Russell
    Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Am Heart J 158:S24-30. 2009
    ..Using baseline data from the HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) study, we examined this relationship...
  44. ncbi Mineralocorticoid receptor antagonism in experimental atherosclerosis
    Sanjay Rajagopalan
    Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA. srajagop@ umich.edu
    Circulation 105:2212-6. 2002
    ..CONCLUSIONS: MR antagonism improves endothelial function and reduces O2*- generation in diet-induced atherosclerosis. Targeting aldosterone by blocking its receptor has potential antiatherosclerotic effects...
  45. ncbi Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction
    Steven J Keteyian
    Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA
    Am Heart J 158:S72-7. 2009
    ..We hypothesized that exercise testing would be safe, as defined by a rate for all-cause death of <0.1 per 1,000 tests and a rate of nonfatal CV events <1.0 per 1,000 tests...
  46. ncbi Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial
    Bertram Pitt
    University of Michigan, Ann Arbor, MI, USA
    Int J Cardiol 143:309-16. 2010
    ..Transatlantic differences in outcomes in heart failure after acute myocardial infarction (AMI) have not been examined in propensity-matched studies...
  47. ncbi Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combinatio
    Kenneth A Jamerson
    University of Michigan Medical Center, Ann Arbor, Michigan
    Am J Hypertens 17:793-801. 2004
    ..05) hypothesized to favor the amlodipine besylate/benazapril group. The ACCOMPLISH study will be performed in the United States and Europe. The first patient was randomizedduring 2003, and the trial should conclude in 2008...
  48. ncbi Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    Am Heart J 150:123-31. 2005
    ..We compared effects of losartan to captopril on mortality, morbidity, and functional status for patients in the ELITE II study...
  49. ncbi Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?
    Apurva Motivala
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Drugs 67:647-55. 2007
    ..Our review of the literature suggests that because of its anti-mineralocorticoid effects, drospirenone in conjunction with estrogen may prevent the development of cardiovascular disease in both pre- and post-menopausal women...
  50. ncbi Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction
    Barry Greenberg
    Department of Medicine, University of California San Diego, San Diego, California 92103, USA, and Division of Tehrapeutics, Clinical Investigation Center INSERM CHU de Nancy Hôpital Jeanne d Arc, Donmartin les Toul, France
    Am J Cardiol 97:34F-40F. 2006
    ....
  51. ncbi Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age
    Audrey H Wu
    University of Michigan, Ann Arbor, MI, USA
    Eur J Heart Fail 12:566-73. 2010
    ..To determine the association between obesity and outcomes in post-acute myocardial infarction (AMI) patients with systolic heart failure (HF)...
  52. ncbi Cardiovascular protection for all individuals at high risk: evidence-based best practice
    George Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Clin Res Cardiol 97:713-25. 2008
    ....
  53. ncbi A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure
    Ali Ahmed
    Department of Medicine, University of Alabama at Birmingham, 1530 Third Avenue South, Birmingham, AL 35294 2041, USA
    Eur Heart J 28:1334-43. 2007
    ..However, the association of low potassium and long-term mortality and morbidity in heart failure (HF) is largely unknown...
  54. ncbi Would you give a beta-blocker and/or aldosterone antagonist to a patient with an ejection fraction (EF) of 30 who has never had symptoms of heart failure?
    Bertram Pitt
    J Am Coll Cardiol 46:CS6. 2005
  55. ncbi Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Circulation 112:1979-84. 2005
    ..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)...
  56. ncbi Sudden death in patients with myocardial infarction
    Bertram Pitt
    N Engl J Med 353:1294-7; author reply 1294-7. 2005
  57. ncbi Aldosterone blockade in patients with acute myocardial infarction
    Bertram Pitt
    Circulation 107:2525-7. 2003
  58. ncbi Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals?
    Bertram Pitt
    N Engl J Med 352:1483-4. 2005
  59. ncbi Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure
    William S Weintraub
    Emory University, 1256 Briarcliff Rd, Suite 1N, Atlanta, GA 30306, USA
    Circulation 111:1106-13. 2005
    ..The present study was performed to evaluate the cost-effectiveness of eplerenone compared with placebo in these patients...
  60. ncbi Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial
    Rakesh Sharma
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
    Eur Heart J 25:1021-8. 2004
    ..2 g/dL, P<0.0001), with no difference between captopril and losartan groups (P>0.3). CONCLUSION: Haemoglobin is an independent predictor of mortality in CHF patients, with anaemic and polycythaemic patients having the worst survival...
  61. ncbi Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure
    Eric B Stanton
    Division of Cardiology, McMaster University and St Joseph s Hospital, Hamilton, Ontario
    Can J Cardiol 21:39-43. 2005
    ..Cardiac troponin I (cTnI) has been validated as a sensitive and specific marker of myocyte damage, and is elevated in some patients with congestive heart failure...
  62. ncbi The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
    James R Sowers
    State University of New York, Brooklyn, USA
    Arch Intern Med 165:161-8. 2005
    ..However, destabilization of hypertension control occurred to some extent in all 3 treatment groups; this phenomenon was seen more often in patients treated with rofecoxib than with the other therapies...
  63. ncbi A new HOPE for aldosterone blockade?
    Bertram Pitt
    Circulation 110:1714-6. 2004
  64. ncbi Eplerenone: will it have a role in the treatment of acute coronary syndromes?
    David J Meier
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029 6574, USA
    Curr Cardiol Rep 6:259-63. 2004
    ..If MR blockade is found to be beneficial in patients with ACS, the potential reduction in morbidity, mortality, and health care costs are profound...
  65. ncbi Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses
    Charles H Hennekens
    Mount Sinai Medical Center Miami Heart Institute, Department of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Boca Raton, FL 33432, USA
    Arch Intern Med 164:40-4. 2004
    ..Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits...
  66. ncbi QT dispersion has no prognostic value in patients with symptomatic heart failure: an ELITE II substudy
    Yi Gang
    Department of Cardiological Sciences, St George s Hospital Medical School, Cranmer Terrace, London, SW17 0RE, United Kingdom
    Pacing Clin Electrophysiol 26:394-400. 2003
    ..In conclusion, increased QT dispersion is not associated with increased mortality in patients with heart failure, and is not suitable to examine drug efficacy in these patients...
  67. ncbi Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 7936, USA
    J Am Coll Cardiol 42:705-8. 2003
    ..We sought to determine whether non-potassium-sparing diuretics (PSDs) in the absence of a PSD may result in progressive heart failure (HF)...
  68. ncbi Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure
    John S Rumsfeld
    Section of Cardiology, Denver VA Medical Center, Denver, Colorado 80220, USA
    Am Heart J 150:961-7. 2005
    ..To evaluate whether depressive symptoms are independently predictive of mortality and hospitalization among patients with acute myocardial infarction (AMI) complicated by heart failure...
  69. ncbi Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan
    Mark S Hansen
    Division of Cardiology of the University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada
    Am J Cardiol 90:969-73. 2002
    ..Flosequinan treatment eliminates this association, highlighting the complexity of the relation between cardiac myocyte damage, drug treatment, and mortality...
  70. ncbi Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk
    Michael A Weber
    SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA
    Blood Press 16:13-9. 2007
    ..It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease...
  71. ncbi Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
    G B John Mancini
    University of British Columbia, Vancouver, British Columbia, Canada
    Am J Cardiol 90:776-8. 2002
  72. ncbi Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure
    Henry A Glick
    Division of General Internal Medicine and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia 19104, USA
    Cardiovasc Drugs Ther 16:53-9. 2002
    ..To use data from the Randomized Aldactone Evaluation Study (RALES) to compare clinical outcomes and costs as part of the assessment of the economic implications of spironolactone treatment of advanced heart failure...
  73. ncbi The Seattle Heart Failure Model: prediction of survival in heart failure
    Wayne C Levy
    University of Washington, Seattle, WA 98177, USA
    Circulation 113:1424-33. 2006
    ....
  74. ncbi Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity
    Jane A Leopold
    Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Med 13:189-97. 2007
    ..These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity...
  75. ncbi Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial
    Sanjay Rajagopalan
    Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    J Clin Hypertens (Greenwich) 8:783-90. 2006
    ..Mechanisms regulating compliance and endothelial function are complex and may not necessarily converge in aging...
  76. ncbi Prediction of mode of death in heart failure: the Seattle Heart Failure Model
    Dariush Mozaffarian
    Harvard Medical School and Harvard School of Public Health, Boston, Mass, USA
    Circulation 116:392-8. 2007
    ..Prediction of mode of death may facilitate decisions about specific medications or devices...
  77. ncbi Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension
    Sanjay Rajagopalan
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
    Am J Cardiol 100:222-6. 2007
    ..In conclusion, addition of simvastatin to valsartan did not incrementally lower BP. However, V/S80 was superior to V and V/S20 in reducing high-sensitivity C-reactive protein...
  78. ncbi Promise of mineralocorticoid receptor blockade in asymptomatic left ventricular dysfunction
    Bertram Pitt
    Hypertension 50:461-2. 2007
  79. ncbi Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study)
    John A Spertus
    Mid America Heart Institute and the University of Missouri, Kansas City, MO, USA
    Am Heart J 143:636-42. 2002
    ....
  80. ncbi Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients
    Stefan D Anker
    Applied Cachexia Research, Department of Cardiology, Charite Campus Virchow Klinikum, Berlin, Germany
    Int J Cardiol 112:234-42. 2006
    ..Treatment with statins may lead to a lower mortality in CHF, independent of cholesterol levels, CHF etiology and clinical status...
  81. ncbi Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, The Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 48:246-53. 2006
    ..These characteristics may lead to a new benefit for this novel hormone therapy in postmenopausal women with hypertension...
  82. ncbi Diuretic use, progressive heart failure, and death in patients in the DIG study
    Michael Domanski
    Clinical Trials Group, Blood Institute, Bethesda, Maryland, USA
    J Card Fail 12:327-32. 2006
    ..71, 95% CI 0.52-0.96, P = .02). CONCLUSION: NPSDs are associated with increased risk of death, CVD, progressive HF death, SCD, and HF hospitalization. A randomized trial is needed to assess the role of NPSDs versus PSDs in HF patients...
  83. ncbi The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction
    Mikhail Kosiborod
    Mid America Heart Institute and University of Missouri Kansas City, Kansas City, Missouri, USA
    J Card Fail 14:27-34. 2008
    ..However, whether changes in hematocrit are associated with changes in health status is unknown...